Urology News and Research

Latest Urology News and Research

Scientists discover MSMB protein in urine can predict prostate cancer risk

British scientists have identified a protein in urine that can help indicate which patients are at an increased risk of developing prostate cancer. The Cancer Research UK Cambridge Research Institute and The Institute of Cancer Research found that the level of MSMB protein in urine could provide a fast and accurate prostate cancer diagnosis for doctors and patients, potentially replacing the currently painful and more costly approach a blood sample.

27 Oct 2010

ENDOMETRIN Vaginal Insert offers effective luteal support in IVF procedures

Ferring Pharmaceuticals Inc. presented study results demonstrating that ENDOMETRIN (progesterone) Vaginal Insert provides effective luteal support compared to intramuscular (IM) progesterone-in-oil (PIO) in patients undergoing in vitro fertilization (IVF) using gonadotropin releasing hormone (GnRH) antagonist.

27 Oct 2010

Caldera Medical relocates to new, larger facility

Caldera Medical today announced its relocation to a new facility in Agoura Hills, CA. The former corporate headquarters of DTS offers Caldera approximately eight times more square footage in anticipation of continued growth as well as capability expansion.

26 Oct 2010

First step in development of artificial human testicle

After more than 30 years of unsuccessful efforts by numerous investigators, researchers have now found a way to propagate primary human Sertoli cells in the laboratory. Derived from the testis, it has been difficult to maintain Sertoli cells, the "nurse" cells responsible for overseeing sperm production, outside of the human body.

26 Oct 2010

Repros commences randomization in Androxal Phase II study in T2DM men with low testosterone

Repros Therapeutics Inc. today announced it has commenced randomization of subjects into its Phase II Androxal® study in the treatment of type 2 diabetes (T2DM) in men with low testosterone. Low testosterone and T2DM are co-morbid conditions in a significant number of men. The study is being conducted at nine sites across the US including both academic and private practices and will enroll up to 150 patients.

25 Oct 2010

NeedleTech increases production area with new 73,000-square foot manufacturing facility

U.S. Congressman James McGovern, State Representative Elizabeth Poirier and local dignitaries joined Theragenics Corporation executives in ribbon cutting ceremonies on October 15 for a new 73,000-square foot manufacturing facility for the company's subsidiary, NeedleTech Products. The new facility increases NeedleTech's production area by 30% or 20,000 square feet, allowing the company to consolidate two separate older facilities into one location. The new building will allow NeedleTech to expand operations, increase R&D and offer more services to its customers.

25 Oct 2010

FDA approves LO LOESTRIN FE tablets for oral contraception

Warner Chilcott plc (Nasdaq: WCRX) today announced that the United States Food and Drug Administration (FDA) has approved LO LOESTRIN FE (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets) for the prevention of pregnancy.

25 Oct 2010

Study evaluates protective effect of airbags on kidneys, upper urinary tract

Occupants in motor vehicles with airbags are much less likely to suffer kidney or renal damage in a crash than are occupants in vehicles without airbags, according to a new study in the September Journal of the American College of Surgeons.

22 Oct 2010

Research suggests lowering cholesterol can reduce benign prostatic hyperplasia

A cholesterol-lowering drug reduced the enlarged prostates of hamsters to the same extent as a drug commonly used to treat benign prostatic hyperplasia (BPH), report researchers at Children's Hospital Boston and their colleagues in the October issue of the Journal of Urology. Together, the drugs worked even better.

22 Oct 2010

Report finds shortage of Mass. physicians is getting worse

The Boston Herald: "The state's physician shortage is getting worse -- with many practices closed to new patients and a critical need for doctors in key specialties, according to a Massachusetts Medical Society report released today. ... The most acute need is for primary-care physicians who practice family or internal medicine. The study called the shortages in those two key areas 'critical.'

21 Oct 2010

Agensys and Seattle Genetics initiate ASG-5ME phase I clinical trial for castration-resistant prostate cancer

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and Seattle Genetics, Inc. today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of castration-resistant prostate cancer. ASG-5ME is an antibody-drug conjugate (ADC) targeting the SLC44A4 antigen and is being co-developed by both companies for the treatment of solid tumors.

21 Oct 2010

NYU Langone Medical Center announces establishment of Smilow Comprehensive Prostate Cancer Center

NYU Langone Medical Center is pleased to announce that it has established The Smilow Comprehensive Prostate Cancer Center with a $5 million gift from Joel E. Smilow, a member of the Board of Trustees at NYU Langone Medical Center and New York University. The Smilow Center is dedicated to providing comprehensive, state-of-the-art personalized care for men with prostate cancer as well as educating men and their families about the disease and the wide range of treatment options available today.

21 Oct 2010

New approaches to explore causes of autoimmunity and immune deficiency diseases

A newly identified regulatory process affecting the biology of immune system T cells should give scientists new approaches to explore the causes of autoimmunity and immune deficiency diseases.

20 Oct 2010

Reports examine drug company payments to doctors

ProPublica: "Drug companies say the millions of dollars they pay physicians for speaking and consulting justly compensates them for the laudable work of educating their colleagues. But a series of lawsuits brought by former employees of those companies allege the money often was used for illegal purposes — financially rewarding doctors for prescribing their brand-name medications.

20 Oct 2010

ProBuild raises $275,000 for City of Hope

ProBuild Company LLC, one of the nation's largest suppliers of building materials to professional contractors, continued its commitment to further cancer and diabetes research by hosting its 2010 Charity Golf Tournament at The Omni Interlocken Resort and Hotel in Broomfield, Colo. ProBuild and its supply partners from across the Rocky Mountain Region together raised more than $275,000 for City of Hope, one of the nation's leading research and treatment centers for cancer, diabetes and other life-threatening diseases.

19 Oct 2010

Robot-assisted surgery effective for five-year prostate cancer control: Study

A first-ever, long-term study of patients who underwent robot-assisted surgery to remove their cancerous prostates found that nearly 87 percent of them had no recurrence of the disease after five years.

19 Oct 2010

Elective surgeries routed to private health system to ease burden

According to the Australian Medical Association, the ACT Government's elective surgery plan is not a long term solution. The plan will see 200 public patients undergoing elective surgery at two private health facilities. The Government has planned to clear up the backlog of elective surgery by using the private health system. At present there is a focus on ear, nose and throat procedures, urology and orthopedic procedures.

17 Oct 2010

Watson Laboratories receives FDA approval for Amlodipine capsules

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for Amlodipine Besylate/Benazepril 5/20mg, 10/20mg, 2.5/10mg, and 5/10mg capsules, the generic equivalent to Novartis' Lotrel capsules.

15 Oct 2010

NinePoint announces completion of $33 million Series A financing

NinePoint Medical, Inc., an emerging leader in the development of in vivo pathology devices, today announced it has completed a $33 million Series A financing led by Third Rock Ventures and Prospect Venture Partners. The company also announced the establishment of its corporate headquarters in Cambridge, Mass. where Charles Carignan, M.D., serves as president and chief executive officer.

14 Oct 2010

FREE educational program to explore discoveries and treatments on women's health issues

A variety of women's health issues occur as the result of stress or from natural functions like aging, childbirth and pregnancy. Urinary incontinence and pelvic prolapse, alterations to female aesthetic appearance and changes to the face, body and breast may result from these normal occurrences.

14 Oct 2010